Cytel
Executive Summary
San Diego-based R&D firm signs a research agreement with Otsu, Japan-based Takara Shuzo Co., Cytel announces June 2. The agreement calls for the two firms to develop Cytel's Theradigm technology for "a non-viral, infectious disease target." Takara will buy a $3 mil. equity stake in Cytel as part of the agreement. In addition, the firms have signed a letter of intent to develop Cytel's ex vivo cellular therapy for treatment of cancers...